Evaluation of therapeutic effects of a pomegranate preparation in patients with hepatic cirrhosis

Evaluation of therapeutic effects of a Panica granatum preparation in patients with hepatic cirrhosis using a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191130045548N1

Enrollment

Registered

2020-07-28

Start date

2020-09-22

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis. Other cirrhosis of liver

Interventions

Intervention 1: Intervention group: In this group, an herbal preparation of pomegranate at 20 mg/kg body weight, is orally given twice in a day for 2 months to the patients with liver cirrhosis. This

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with hepatic cirrhosis

Exclusion criteria

Exclusion criteria: Non-cirrhotic patients Cirrhotic patients who have progressed to liver transplantation

Design outcomes

Primary

Measure	Time frame
Model for End-Stage Liver Disease (MELD) score. Timepoint: The beginning of the study (or before administration of pomegranate preparation) and two months after (two months after administration of the preparation). Method of measurement: ALT (Alanin Transaminase), AST (Aspartate Aminotransferase), ALP ( Alkaline Phosphatase), INR ( International Normalized Ratio), Albumin, creatinine, bilirubin, also clinical investigations for presence of ascites and hepatic encephalopathy and calculation of MELD score Model for End-Stage Liver Disease.	—

Measure

Time frame

Model for End-Stage Liver Disease (MELD) score. Timepoint: The beginning of the study (or before administration of pomegranate preparation) and two months after (two months after administration of the preparation). Method of measurement: ALT (Alanin Transaminase), AST (Aspartate Aminotransferase), ALP ( Alkaline Phosphatase), INR ( International Normalized Ratio), Albumin, creatinine, bilirubin, also clinical investigations for presence of ascites and hepatic encephalopathy and calculation of MELD score Model for End-Stage Liver Disease.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArezoo Rajabian

Mashhad University of Medical Sciences

rajabianar@mums.ac.ir0098 38828265

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026